2617 — TransThera Sciences (Nanjing) Share News
0.000.00%
Last trade - 00:00- HK$3.59bn
- HK$2.51bn
TransThera at 6-week high on China regulator's nod to market cancer drug
Brief: TransThera Sciences (Nanjing) Says NMPA Grants Marketing Approval For Yochanra (Tinengotinib Tablets)
Brief: Transthera Sciences (Nanjing) Says NMPA Approves Phase II Trial Of TT-973 With Firmonertinib Mesylate
TransThera Sciences jumps most in nearly four months on share buyback plan
Brief: TransThera Sciences (Nanjing) Inc And Shanghai Allist To Collaborate For NSCLC Clinical Trial
Brief: TransThera Sciences (Nanjing) To Place 3.8 Mln New H Shares At HK$40.83 Per Share
Brief: Transthera Sciences (Nanjing) Inc Announces Placing Of 5.1 Million Shares At HK$57.03 Per Share
Brief: Transthera Sciences (Nanjing) FY Loss Attributable Rmb296 Million
Brief: Transthera Sciences (Nanjing) To Place 2.1 Million Shares At HK$92.85 Per Share
HK-listed TransThera climbs on new drug application
Brief: Transthera Sciences (Nanjing) Says NMPA Accepts New Drug Application For Tinengotinib Tablets
TransThera climbs on product inclusion in priority review list
Brief: Transthera Sciences (Nanjing) Inc Announces Collaboration With Neurocrine Biosciences Inc For NLRP3 Inhibitors
Brief: Transthera Sciences (Nanjing) Inc Receives IND Approval From NMPA
Brief: TransThera Sciences (Nanjing) Inc Posts HY Loss Attributable RMB122.9 Million
Brief: Transthera Sciences (Nanjing) Inc Says Grant Of Tinengotinib (Tt-00420) Fast Track Designation